<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285596</url>
  </required_header>
  <id_info>
    <org_study_id>178-CL-072</org_study_id>
    <secondary_id>2008-006005-16</secondary_id>
    <nct_id>NCT01285596</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex</brief_title>
  <official_title>An Open-label, Randomized, 2-way Crossover Study to Evaluate the Pharmacokinetics of Mirabegron and Its Metabolites in Healthy Young and Elderly Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Young and elderly, male and female subjects are each given 2 different doses of mirabegron&#xD;
      for 7 days each. Levels of mirabegron in the blood are assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of pharmacokinetics of mirabegron and its metabolites</measure>
    <time_frame>Days 6 - 14 + Days 21 - 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impedance cardiography assessed through evaluation of cardiac outputs, stroke volume, systemic vascular resistance index, mean arterial blood pressure and heart rate</measure>
    <time_frame>Days -1, 1, 6 and 7</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">75</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Pharmacokinetics of Mirabegron</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>oral</description>
    <other_name>YM178</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy elderly subject aged 55 years or more OR Healthy young subject aged 18 to 45&#xD;
             years, inclusive&#xD;
&#xD;
          -  Male must agree to sexual abstinence and/or use a highly effective method of birth&#xD;
             control from screening until 3 months after last dose of study medication&#xD;
&#xD;
          -  Female subject must be of non-child bearing potential, i.e. post menopausal,&#xD;
             surgically sterilized (e.g. tubal ligation), hysterectomy in medical history, or must&#xD;
             practice an adequate non-hormonal contraceptive method to prevent pregnancies.&#xD;
             Non-hormonal contraceptive methods are defined as:&#xD;
&#xD;
               -  Sexual abstinence from 1 month before admission until 3 months after discharge,&#xD;
                  OR&#xD;
&#xD;
               -  Subject's sexual partner has been surgically sterilized (since at least 3 months&#xD;
                  prior to the screening), OR&#xD;
&#xD;
               -  Subject is under two (2) of the following contraceptive methods: A) Diaphragm&#xD;
                  with spermicide; B)Intrauterine device; C)Sexual partner is using condoms in&#xD;
                  combination with a spermicidal creamDuring the study the subject is willing to&#xD;
                  use 1 of the 3 following contraceptive methods: diaphragm with spermicide,&#xD;
                  intrauterine device or partner is using condoms in combination with a spermicidal&#xD;
                  cream&#xD;
&#xD;
          -  Body Mass Index between 18.5 and 30.0 kg/m2, inclusive&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity to Mirabegron or any components of the formulation&#xD;
             used&#xD;
&#xD;
          -  Pregnant or breast feeding within 6 months before screening assessment&#xD;
&#xD;
          -  Any of the liver function tests (i.e. ALT, AST and Alkaline phosphatase) above the&#xD;
             upper limit of normal at repeated measurements&#xD;
&#xD;
          -  Any clinically significant history of asthma, eczema, any other allergic condition or&#xD;
             previous severe hypersensitivity to any drug (excluding non-active Hay-fever)&#xD;
&#xD;
          -  Any clinically significant history of any other disease or disorder -&#xD;
             gastrointestinal, cardiovascular, respiratory, renal, hepatic, neurological,&#xD;
             dermatological, psychiatric or metabolic as judged by the investigator&#xD;
&#xD;
          -  Any clinically significant abnormality following the investigator's review of the&#xD;
             pre-study physical examination, ECG and clinical laboratory tests&#xD;
&#xD;
          -  A hemoglobin value &lt;13 g/dl (8.1 mmol/l) for males or &lt;12 g/dl (7.5 mmol/l) for&#xD;
             females OR a hematocrit value &lt;40.0% for males or &lt;37% for females OR a Red Blood Cell&#xD;
             count &lt;4.5 T/l (4500 mm3) for males or &lt;3.8 T/l (3800 mm3) for females at screening&#xD;
             and/or on the day of admission into the clinical unit&#xD;
&#xD;
          -  Abnormal pulse and/or blood pressure measurements at the pre-study visit as follows:&#xD;
             Pulse &lt;40 or &gt;90 bpm; mean systolic blood pressure &gt;160 mmHg (elderly) or &gt;140 mmHg&#xD;
             (young); mean diastolic blood pressure &gt;100 mmHg (elderly) or &gt;90 mmHg (young), blood&#xD;
             pressure measurements taken in triplicate after subject has been resting in supine&#xD;
             position for 5 min; pulse will be measured automatically&#xD;
&#xD;
          -  A marked baseline prolongation of QT/QTc interval after repeated measurements of &gt;450&#xD;
             ms, a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias&#xD;
             or torsades de pointes, structural heart disease, or a family history of Long QT&#xD;
             Syndrome (LQTS)&#xD;
&#xD;
          -  Use of any prescribed or OTC (over-the-counter) drugs (including vitamins, natural and&#xD;
             herbal remedies, e.g. St. John's wort) in the 2 weeks prior to admission to the&#xD;
             Clinical Unit, except for occasional use of paracetamol (up to 3 g/day)&#xD;
&#xD;
          -  Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampin) in the 3&#xD;
             months prior to admission to the Clinical Unit&#xD;
&#xD;
          -  Any use of drugs of abuse within 3 months prior to admission to the Clinical Unit&#xD;
&#xD;
          -  History of drinking more than 21 units of alcohol for males or more than 14 units of&#xD;
             alcohol per week for females (1 unit = 270 cc of beer or 40 cc of spirits or 1 glass&#xD;
             of wine) within 3 months prior to admission to the Clinical Unit&#xD;
&#xD;
          -  Positive test for drugs of abuse or positive alcohol test at screening and/or on the&#xD;
             day of admission into the clinical unit&#xD;
&#xD;
          -  History of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day&#xD;
             within 3 months prior to admission to the Clinical Unit&#xD;
&#xD;
          -  Participation in any clinical study within 3 months or participation in more than 3&#xD;
             clinical studies within 12 months, prior to the expected date of enrolment into the&#xD;
             study&#xD;
&#xD;
          -  Donation of blood or blood products within 3 months prior to admission to the Clinical&#xD;
             Unit&#xD;
&#xD;
          -  Positive serology test for HBsAg, anti HAV (IgM), anti-HCV or anti-HIV 1+2&#xD;
&#xD;
          -  Subjects who, in the opinion of the investigator, are not likely to complete the trial&#xD;
             for any reason&#xD;
&#xD;
          -  Any clinical condition, which, in the opinion of the investigator would not allow safe&#xD;
             completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=661</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <reference>
    <citation>Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G, van Marle S, Kerbusch V, van Gelderen M. Pharmacokinetic properties of mirabegron, a Î²3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther. 2012 Oct;34(10):2144-60. doi: 10.1016/j.clinthera.2012.09.010.</citation>
    <PMID>23063375</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>January 18, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2011</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Cardiography</keyword>
  <keyword>Impedance</keyword>
  <keyword>Age groups</keyword>
  <keyword>Gender Identity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

